Related Experiment Video
Updated: Jan 28, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner?
Christos Mantis1, Dimitrios Alexopoulos2
1Cardiology Department, Konstantopoulio General Hospital, Athens, Greece.
Insights
Dual antithrombotic therapy (DAT) may be a safer alternative to triple antithrombotic therapy (TAT) for patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI). DAT reduces bleeding risk while maintaining similar efficacy for preventing ischemic events.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation affects approximately 7% of patients undergoing percutaneous coronary intervention (PCI) with stent implantation.
- Optimal antithrombotic treatment in this high-risk population is a significant clinical challenge.
- Triple antithrombotic therapy (TAT) is effective but associated with increased bleeding risk.
Purpose of the Study:
- To define the role of dual antithrombotic therapy (DAT) versus TAT in patients with atrial fibrillation undergoing PCI.
- To analyze controversial issues and future expectations regarding antithrombotic strategies.
Main Methods:
- Review of recent clinical trials comparing DAT and TAT.
- Analysis of efficacy and safety data, focusing on bleeding and ischemic events.
- Expert opinion and consensus on simplified antithrombotic strategies.
Main Results:
- Recent trials suggest DAT (single antiplatelet + oral anticoagulant) reduces bleeding risk compared to TAT (dual antiplatelet + oral anticoagulant).
- DAT appears to maintain similar efficacy in preventing ischemic events as TAT.
- A simplified DAT strategy using a non-vitamin K antagonist oral anticoagulant and clopidogrel is gaining expert support.
Conclusions:
- DAT represents an attractive, simplified strategy for many patients with atrial fibrillation undergoing PCI.
- Further research is needed to address remaining controversies and establish definitive guidelines.
- Optimizing antithrombotic treatment balances efficacy and safety in this complex patient group.
Abstract:
Approximately 7% of patients undergoing percutaneous coronary intervention (PCI) with stent implantation have atrial fibrillation. The optimal antithrombotic treatment in such of patients remains one of the most challenging and difficult scenarios in Cardiology. Triple antithrombotic therapy (TAT), consisting of dual antiplatelet therapy plus an oral anticoagulant, has been used for decades in order to reduce ischemic and thromboembolic events, while significantly increasing the risk for severe bleeding. Recently, results of several clinical trials suggest that the use of dual antithrombotic therapy (DAT), consisting of single antiplatelet therapy plus an oral anticoagulant, reduces the risk of bleeding, while maintaining the same level of efficacy as compared to TAT. These data have been interpreted in a variety of ways, often giving conflicting recommendations and leaving many unanswered questions on the optimal antithrombotic treatments of patients with atrial fibrillation who undergo PCI. DAT consisting of a non-vitamin K antagonist oral anticoagulant and clopidogrel, while omitting aspirin from the immediate post discharge period, appears as an attractive, simplified strategy for most patients and supported by many experts in the field. In this review we aim to better define the role of DAT versus TAT in atrial fibrillation patients undergoing PCI and analyze remaining controversial issues and future expectations.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Gene Therapy
Group Therapy

